Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16215853 | 0.81 | HRH3 (0.58) | HRH3 | |
| Hydrochloric Acid SCHEMBL16207754 | 0.81 | HRH3 (0.57) | HRH3 | |
| SCHEMBL16207716 | 0.79 | GPR119 (0.44) | HRH3MAPTGPR119MEN1KMT2A | |
| SCHEMBL16215830 | 0.77 | ACKR3 (0.43) | HRH3MAPTNOTUMGPR119SMN1; SMN2 | |
| SCHEMBL16207706 | 0.76 | GPR119 (0.48) | HRH3GPR119MEN1KMT2A | |
| SCHEMBL16207744 | 0.76 | GPR119 (0.48) | HRH3GPR119MEN1KMT2A | |
| SCHEMBL16207616 | 0.76 | CA1 (0.46) | NOTUMGPR119 | |
| SCHEMBL2554613 | 0.73 | GPR119 (0.65) | HRH3GPR119 | |
| SCHEMBL21004332 | 0.71 | FPR2 (0.46) | HRH3MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21004251 | 0.71 | SMN1; SMN2 (0.55) | HRH3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045553-A1 | PHENYLTRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045553-A1 | PHENYLTRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045553-A1 | PHENYLTRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2799436-A1 | PHENYLTRIAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-11-05 | — | — | EP | disclosed |
| EP-2799436-A1 | PHENYLTRIAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045553-A1 | PHENYLTRIAZOLE DERIVATIVE | PER2, BACE1, MAPT | HRH3 56/4885MAPT 3/4885NOTUM 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.